David Moatazedi Net Worth

The estimated Net Worth of David Moatazedi is at least $22.2 Million dollars as of 4 June 2024. Mr. Moatazedi owns over 471,432 units of Evolus Inc stock worth over $8,144,239 and over the last 8 years he sold EOLS stock worth over $11,819,303. In addition, he makes $2,278,810 as President, Chief Executive Officer und Director at Evolus Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Moatazedi EOLS stock SEC Form 4 insiders trading

David has made over 15 trades of the Evolus Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 471,432 units of EOLS stock worth $6,006,044 on 4 June 2024.

The largest trade he's ever made was selling 471,432 units of Evolus Inc stock on 4 June 2024 worth over $6,006,044. On average, David trades about 30,802 units every 38 days since 2017. As of 4 June 2024 he still owns at least 533,349 units of Evolus Inc stock.

You can see the complete history of Mr. Moatazedi stock trades at the bottom of the page.

David Moatazedi biography

David Moatazedi serves as President, Chief Executive Officer, Director of the Company. He was the Senior Vice President at Allergan, Inc. (“Allergan”), and division head of the U.S. Medical Aesthetics division, which includes facial aesthetics, plastic surgery, regenerative medicine, body contouring, and skin care products from March 2016 to May 2018. Since March 2017, Mr. Moatazedi has served as a member of the board of directors of Obalon Therapeutics, Inc., a public medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Mr. Moatazedi has worked in various leadership capacities within Allergan since March 2005, including as Vice President, Sales and Marketing of the U.S. Facial Aesthetics division from August 2014 to March 2016 and Vice President, Sales and Market of the U.S. Plastic Surgery division from February 2013 to August 2014. Prior to Allergan, Mr. Moatazedi was a district manager at Novartis Pharmaceuticals for the Dermatology division. Mr. Moatazedi holds an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.

What is the salary of David Moatazedi?

As the President, Chief Executive Officer und Director of Evolus Inc, the total compensation of David Moatazedi at Evolus Inc is $2,278,810. There are 1 executives at Evolus Inc getting paid more, with Michael Jafar having the highest compensation of $3,929,160.

How old is David Moatazedi?

David Moatazedi is 42, he's been the President, Chief Executive Officer und Director of Evolus Inc since 2018. There are 9 older and 2 younger executives at Evolus Inc. The oldest executive at Evolus Inc is Peter Farrell, 78, who is the Independent Director.

What's David Moatazedi's mailing address?

David's mailing address filed with the SEC is 520 Newport Center Dr #1200, Newport Beach, CA 92660, USA.

Insiders trading at Evolus Inc

Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox und 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.

What does Evolus Inc do?

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Complete history of Mr. Moatazedi stock trades at Biomerica, Obalon Therapeutics Inc und Evolus Inc

Evolus Inc executives and stock owners

Evolus Inc executives and other stock owners filed with the SEC include:

• Michael Jafar,
  Chief Commercial Officer
• David Moatazedi,
  President, Chief Executive Officer, Director
• Rui Avelar,
  Chief Medical Officer, Head of Research & Development
• David Moatazedi,
  Pres, CEO & Director
• Lauren Silvernail,
  Chief Financial Officer, Executive Vice President - Corporate Development
• Lauren P. Silvernail,
  CFO & Exec. VP of Corp. Devel.
• Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
  Chief Medical Officer and Head of R&D
• Karah Parschauer,
  Independent Director
• Peter Farrell,
  Independent Director
• Vikram Malik,
  Chairman of the Board
• David Gill,
  Independent Director
• Robert Hayman,
  Independent Director
• Simone Blank,
  Director
• Tram Bui,
  IR Contact Officer
• Jeff Plumer,
  General Counsel
• Jessica Novak,
  Sr. VP of HR
• Crystal Muilenburg,
  Chief Marketing Officer
• Kurt Knab,
  VP of Sales
• Jeffrey J. Plumer,
  Gen. Counsel
• David K. Erickson,
  VP of Investor Relations
• Biopharma, Inc. Aeon,
  
• Sandra Beaver,
  Chief Financial Officer
• Crystal Muilenburg,
  Chief Marketing Officer
• Albert G Iii White,
  Director
• Kristine Romine,
  Director
• Bosun Hau,
  Director
• 1 Llc Alphaeon,
  
• Brady Stewart,
  Director
• Tomoko Yamagishi Dressler,
  Chief Marketing Officer
• Inc. Medytox,